NovoCure engages in the development, manufacture and commercialization of tumor treating fields for the treatment of solid tumors. The Company markets its proprietary therapy, TTFields delivery system, for use as a monotherapy treatment for adult patients with glioblastoma brain cancer. It is also involved in conducting clinical trials for the use of TTFields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer and mesothelioma.
Market capitalization (22-Sep-2017)
Closing share price (22-Sep-2017)